Xilio Therapeutics Presents Preclinical Tumor-Selective Activity and Tolerability Data for XTX101 at Frontiers in Cancer Immunotherapy Virtual Symposium

Xilio Therapeutics Appoints Christina Rossi to its Board of Directors

Xilio Therapeutics Strengthens Management Team with R&D Leadership Appointments

Xilio Therapeutics Strengthens Leadership Team with the Addition of Two Executives

Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline